Differential diagnosis of testicular embryonal rhabdomyosarcoma and testicular seminoma with enhanced CT: a retrospective study

• by Zhixu Zhang, Pan Liang, Songwei Yue, Yonggao Zhang, Hongyan Zhang, Zhigang Zhou, Jianbo Gao

• June 3, 2026

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

• June 1, 2026

• 5 min

Multimodal feature fusion model for breast mass malignant risk stratification

• by Shengxin Pei, Xiumei Tang, Hongxia Su, Jingyan Liu, Zihan Lan, Siyu Wang, Yulan Peng

• June 3, 2026

Effectiveness of a culturally adapted psychoeducational intervention for family caregivers of children with hematologic malignancy: a randomized controlled trial

• by Zhiyu Ye, Yuanyuan Zhang, Lisha Dai, Wentian Li, Fang Wang

• June 2, 2026